Immunic (IMUX) vs PolyPid (PYPD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PolyPid (PYPD) has outperformed Immunic (IMUX) over the past year, gaining 42.9% versus a loss of 15.8%. Over five years, IMUX leads with a -91.3% price change compared with -97.8% for PYPD. Immunic is the larger company by market cap ($103.2 million vs $99.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMUX | PYPD |
|---|---|---|
| Share price | $7.56 | $4.90 |
| Market cap | $103.15M | $99.53M |
| 1-day change | -0.92% | -1.01% |
| YTD return | +41.57% | +12.90% |
| 1-year return | -15.81% | +42.86% |
| 5-year return | -91.28% | -97.83% |
| EPS (TTM) | $-3.83 | $-1.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.43 | $5.73 |
| 52-week low | $5.06 | $3.06 |
| Distance from 52-week high | -56.63% | -14.49% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +469.97% | +139.80% |
| Average volume | 284.68K | 176.73K |
| Shares outstanding | 13.64M | 20.31M |
| Employees | 100 | 69 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PYPD has outperformed IMUX by 58.7 percentage points over the past year.
About Immunic
IMUX stock →Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Healthcare · Biotechnology · 100 employees
About PolyPid
PYPD stock →PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.
Healthcare · Biotechnology · 69 employees
IMUX vs PYPD FAQ
Which is bigger, Immunic or PolyPid?
Immunic (IMUX) is larger, with a market capitalization of $103.15M compared with $99.53M for PolyPid (PYPD).
Which stock has performed better over the past year, IMUX or PYPD?
PYPD returned +42.86% over the past 12 months, compared with -15.81% for IMUX (price return, excluding dividends). Past performance does not predict future results.
Are Immunic and PolyPid in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.